Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2000

View Archived Issues

AxyS enters drug design agreement with Bristol-Myers Squibb

Generex receives U.S. patent for large-molecule pharmaceutical delivery

Porphyrins designed at Schering for PDT and MRI

Case study of (-)-OSU-6162 in Huntington's disease patient

Cephalon's Provigil beneficial in sleep apnea

Dainippon and Questcor modify antibacterial research agreement

Lorus Therapeutics receives US patent for antisense cancer therapies

U.S. patent issued for B-cell lymphoma therapy

Progenics reviews progress in development of new AIDS therapies at major conference

Novogen initiates phase I clinical trial with potential prostate cancer treatment

NuChem anticancer agent inhibits human melanoma metastasis in mice

Rhinocort Aqua available across U.S. for allergy relief

New products enter the pipeline at Bone Care

BASF initiates phase III clinical trials of D2E7

Targretin gel formulation granted priority review status

Inhibitors of cGMP-PDEs under study at Bayer

Potent cell adhesion inhibitors result from Pharmacia & Upjohn/Tanabe Seiyaku collaboration

Hair growth promoter described by BMS for use in male pattern baldness

NIA trial will compare cognitive effects of COX-2 inhibitor versus nonselective NSAID

HMR contributes novel antihistaminics to Aventis pipeline

Idun patents new dipeptide mimetics that inhibit ICE/ced-3 cysteine proteases

Prednisone not effective in AD

Research on new anti-HIV agents continues at DuPont

MMP-9: a new target for anti-HIV drugs?

FluMist provides unexpected protection against flu strain not covered by vaccine in children

Lack of resistance to investigational NNRTI during early clinical trials

Triangle presents first clinical data for DAPD at major scientific forum

LF-16-0687 shows further promise for treatment of traumatic brain injury

News from 31st SGO: excellent results obtained with OvaRex in selected heavily pretreated patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...